Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer

Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer

Background Programmed death 1 (PD-1) inhibitor demonstrated durable antitumor activity in advanced esophageal squamous cell carcinoma (ESCC), but the clinical benefit of perioperative immunotherapy in ESCC remains unclear. This study evaluated the efficacy and safety of neoadjuvant chemoradiotherapy...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Qiang Liu, Qing Ye, Xin Xu, Lei Shen, Yao Zhang, Bin Hu, Haiyan Chen, Xiaojing Zhao, Zhiyong Sun, Haiping Lin, Ling Rong, Xiaohang Wang, Yong-Rui Bai, Xiumei Ma
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: BMJ Publishing Group 2024-03-01
Cyfres:Journal for ImmunoTherapy of Cancer
Mynediad Ar-lein:https://jitc.bmj.com/content/12/3/e008631.full

Rhyngrwyd

https://jitc.bmj.com/content/12/3/e008631.full

Eitemau Tebyg